Hepatitis E virus (HEV) is a common cause of acute viral hepatitis worldwide (1). There are 4 genotypes of HEV. Genotypes 1 and 2 infect humans in developing countries in areas with poor sanitation; transmission occurs through the fecal–oral route, causing occasional large outbreaks or frequent sporadic cases. Genotype 1 is found in Asia and Africa, and genotype 2 is found in Mexico and Africa. Genotypes 3 and 4 are transmitted zoonotically from animal reservoirs in industrialized and developing countries, mainly through consumption of uncooked or undercooked meat, and are responsible for sporadic cases of disease (1). In the Netherlands, genotype 3 is endemic in pigs and responsible for cases in humans.

The mean incubation period for hepatitis E is 40 days (range 15–60 days). Symptoms range from subclinical to fulminant and include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, jaundice, joint pain, and hepatomegaly (1).

Hepatitis E is usually a self-limiting disease. The mortality rate for fulminant hepatitis is 0.5%–4%. Pregnant women, immunosuppressed persons, and persons with preexisting liver disease are at risk for severe hepatitis E. However, fulminant liver disease in immunocompetent persons has also been reported (2). Mortality rates for hepatitis E caused by genotype 1 for pregnant women are 20%–25% (3,4).

A previous HEV infection is characterized by the presence of specific IgG and is assumed to protect against reinfection. There is cross-neutralization among all genotypes (5).

Travelers from industrialized countries to developing countries are assumed to be at risk for acquiring an HEV infection through the fecal–oral route (genotypes 1 and 2). A vaccine against HEV is available only in China (4).

A study that included data in the GeoSentinel surveillance network for returned travelers with infectious gastrointestinal diseases during 1996–2005 reported a proportionate HEV illness rate of 1.2 cases/1,000 ill returned travelers (6). A recent case report identified a nonpregnant immunocompetent traveler who returned to Canada from India and was given a diagnosis of HEV infection, in whom fulminant liver failure developed (2). A study in Israel of 4,970 ill returning travelers during 1997–2012 reported 49 (1%) with acute hepatitis: 19 travelers were given a diagnosis of hepatitis E, of whom 16 contracted their cases on the Indian subcontinent (7). The estimated risk for acquiring HEV for this study was 3.2 cases/100,000 travelers.

A prospective study of 1,206 short-term travelers from the Netherlands to subtropical and tropical countries (8), a prospective study of 105 long-term backpackers in Israel (9), and a prospective study of American missionaries (10) showed no seroconversions for HEV. Another prospective study of 356 short-term travelers from the United States reported 4 (1.7%) seroconversions (11). However, because...
seroconversions were found only for samples obtained 6 months after return of travelers and not in samples obtained 6 weeks posttravel, HEV might have been contracted after their return.

To our knowledge, no recent prospective studies of long-term travelers have been conducted. Because the risk for hepatitis E in subtropical and tropical countries might have increased, and the sensitivity of ELISAs for diagnosing HEV infection has improved over the past decade (3), we determined the incidence and risk factors of acquiring hepatitis E among long-term travelers (12–52 weeks) from the Netherlands to subtropical and tropical countries.

Methods

Study Population and Design

This study was conducted as part of a larger, prospective, monocenter study of immunocompetent travelers ≥18 years of age who visited the Public Health Service Travel clinic in Amsterdam, the Netherlands, during December 2008–September 2011. All clients planning to travel to subtropical or tropical countries for 12–52 weeks were invited to participate. Subtropical and tropical countries were defined as those with moderate to high risk for hepatitis A according to the World Health Organization (12). All participants consulted a nurse or physician specialized in travel medicine, and oral and written information was provided about how to avoid travel-related diseases. The study was approved by the Medical Ethics Committee of the Academic Medical Center in Amsterdam.

At their return, travelers were asked additional questions regarding behavior during travel, including drinking unboiled tap water or water from natural sources. Pretravel written informed consent was obtained, and travelers were interviewed by a nurse or physician about travel purpose, travel duration, planned destination(s), and demographic details.

Participants were given a digital thermometer (Hui-keshoven Medical, Tiel, the Netherlands) and asked to record their temperatures if they felt feverish while traveling. Travelers kept a structured, weekly travel diary until 2 weeks after return and recorded their itinerary, symptoms, and physician visits while ill. Predefined symptoms that could be related to hepatitis E were fever and vomiting. It was also possible to report other complaints. Diaries were completed on paper or digitally. Travelers received a weekly email reminder and were seen 2–6 weeks after return. Blood samples were obtained before and after travel. The pretravel sample was tested only if the posttravel sample tested was positive for antibodies against HEV.

Primary regions visited were grouped into regions according to the classification of the United Nations Country Classification with some modifications. For our study, Oceania included only Melanesia, Micronesia, and Polynesia and was merged with Southeast Asia because New Zealand and Australia matched exclusion criteria for participating. Latin America was divided into South America and the Caribbean/Central America.

Laboratory Methods

Blood samples were immediately stored at 6°C, centrifuged, and frozen at −80°C. We tested serum samples for HEV IgG by using an ELISA (Wantai Biologic Pharmacy Enterprise, Beijing, China), according to the manufacturer’s instructions. This assay had a reported sensitivity of 98% but does not discriminate between different virus genotypes. If HEV IgG was detected in a posttravel sample, pretreatment samples were also tested. Presence of HEV IgG in a pretravel sample was regarded as evidence of previous HEV infection. A recent infection was defined as a positive posttravel sample and a negative pretravel sample.

Data Analysis

We calculated risk factors for previous HEV infection by using SPSS version 19.0 (IBM, Armonk, NY, USA) to obtain prevalence, univariable and multivariable prevalence ratios (PRs), and 95% CIs by means of logistic regression modeling. A p value <0.05 was considered statistically significant. All variables with p values <0.10 by univariable analysis were included in a multivariable model.

We calculated the attack rate of a recent HEV infection by dividing the number of seroconversions by the total number of participants still at risk for infection (i.e., all travelers who did not have HEV antibodies pretravel). We also calculated incidence rates by dividing the number of seroconversions by the total number of travel weeks of travelers still at risk. Person-time denominators for seroconversion were divided in half, assuming that the infection occurred halfway through travel.

We used univariable Poisson regression models to examine the effect of covariates (sex, age, travel purpose, primary destination, hospital admission) on seroconversion. Variables with p values <0.10 in univariable analysis were included in multivariable analysis. Outcomes were expressed as incidence rate ratios with 95% CIs. A p value <0.05 was considered statistically significant.

Results

Study Population

During December 2008–September 2011, a total of 685 persons who intended to travel to subtropical and tropical countries for 12–52 weeks provided informed consent. Of
these persons, 81 (12%) were excluded after completion of the study: 42 had their travel arrangements changed and no longer met the study criteria, 38 were lost to follow-up, and 1 did not provide a posttravel blood sample. The remaining 604 persons formed the study population.

Median age of the study population was 25 years (interquartile range [IQR] 23–29 years), ≈66.6% were female, and 20% had never been to subtropical or tropical regions. Tourism was the main purpose for traveling (62.9%). Median interval between the first sample and departure was 38 days (IQR 20–55 days). Median interval between return and the second blood sample was 25 days (IQR 21–33 days).

Previous HEV Infection
A total of 89 of 604 persons were positive for HEV pretravel and posttravel, which indicated previous HEV infection, for a pretravel seroprevalence rate of 14.7% (Table 1). Univariate analysis indicated that previous HEV infection showed a positive correlation with older age, a nonwestern origin, and a history of travel to subtropical or tropical regions. Multivariate analysis showed that age, travel history, and nonwestern origin remained major predictors for previous HEV infection.

HEV Infection Acquired during Current Travel
IgG seroconversion was found for 19/515 travelers, resulting in an attack rate of 3.7% and an incidence of 1.8 (95% CI 1.1–2.8) per 1,000 person-weeks. We obtained characteristics, attack rates, and incidence for recent HEV infections (seroconversions) (Table 2). At return, 32% (163/510) of participants reported they had used unboiled or untreated tap water for consumption, 19 did not remember, and 5 had missing results. The remaining 328 travelers did not consume unboiled or untreated water. Six persons who showed seroconversion reported having drunk unboiled or untreated tap water; 1 person had a missing result. Logistic regression of characteristics tested did not identify any major risk factors for acquiring HEV infection during travel.

A combination of these factors is possible. Therefore, comparison of results of previous prospective and seroprevalence studies with those of our study should be interpreted with caution. We also found no major risk factors for acquiring HEV infection during travel.

Previous travel to subtropical region
A total of 31 (6%) of 515 participants were admitted to a hospital while abroad, of whom 1 person who showed seroconversion was admitted because of symptoms of fever and dehydration caused by diarrhea. Jaundice, dark-colored urine, and light-colored stool were not reported as other complaints in the diary.

Discussion
In this prospective study of long-term travelers from the Netherlands to subtropical and tropical countries, we found a substantial hepatitis E attack rate of 3.7% and an incidence of 1.8 cases/1,000 person-weeks. Results were obtained by using an HEV IgG ELISA and were higher than those in the 4 previous prospective studies of travelers (8–11).

The relatively high HEV seroconversion rate we found compared with those for previous prospective studies could be explained by an increase of hepatitis E incidence in developing countries over time. However, our results probably reflect improved sensitivity of currently available tests compared with those used in these previous studies. A combination of these factors is possible. Therefore, comparison of results of previous prospective and seroprevalence studies with those of our study should be interpreted with caution. We also found no major risk factors for acquiring HEV infection during travel.

Two nonprospective studies reported that hepatitis E is associated with travel to southern Asia (7,13). We found higher attack rates and incidences for southern Asia, other regions of Asia, and Central America than for Africa.

Table 1. Characteristics of 604 travelers who visited a travel clinic for pretravel advice and prevalence of previous HEV infection, the Netherlands, December 2008–September 2011*

| Characteristic                        | Travelers | HEV IgG positive pretravel | Univariable analysis | Multivariable analysis |
|--------------------------------------|-----------|----------------------------|----------------------|------------------------|
|                                      | N         | PR (95% CI)                | p value              | PR (95% CI)            | p value              |
|                                      |           | 604 (14.7)                 | 1.0 (1.01–1.07)      | 1.0 (1.01–1.06)        | 0.01                  |
| Median age, y (IQR)                  |           |                            | 25 (23–29)           | 26 (23–30)             | 1.0 (1.01–1.07)      | 0.002                 |
| Sex                                  |           |                            |                      |                        | 1.0                    | 0.43                   |
| M                                    | 215 (35.6)| 35 (16.3)                 | 1.2 (0.76–1.92)      | 1.0 (1.06–1.92)        | 0.03                  |
| F                                    | 389 (64.4)| 54 (13.9)                 | 1.0                    | 0.34                   |                       |
| Region of birth                      |           |                            | 215 (35.6)           | 35 (16.3)             | 1.2 (0.76–1.92)      | 0.03                  |
| Western (the Netherlands), n = 563   |           |                            | 590 (97.7)           | 84 (14.2)              | 1.0 (1.0–1.0)        | 0.034                 |
| Nonwestern                           |           |                            | 14 (2.3)             | 5 (35.7)               | 3.4 (1.1–10.23)      | 3.6 (1.5–11.28)       |
| Previous travel to subtropical region|           |                            |                       |                        | 1.0 (1.06–1.92)      | 0.03                  |
| No                                   | 122 (20.2)| 7 (5.7)                   | 1.0                    | 0.003                  | 1.0                   | 0.01                  |
| Yes                                  | 482 (79.8)| 82 (17.0)                 | 3.4 (1.5–7.5)        | 2.9 (1.27–6.45)        |                       |

*Values are no. (%) except as indicated. Bold indicates statistical significance. HEV, hepatitis E virus; IQR, interquartile range; PR, prevalence ratio.
South America, and South America, but this finding did show a major difference.

In 2 other studies, travelers visiting friends and relatives were found to be at greater risk than tourist travelers for infectious diseases such as typhoid fever (6) and hepatitis E (14). Our study showed a higher attack rate (14%) and incidence (5.3 cases/1,000 person-weeks) for travelers visiting friends and relatives than for persons traveling for tourism or work/study, but this association was not strong. This finding could be caused by the small numbers of travelers visiting friends and relatives.

The pretravel seroprevalence of 15% we found was higher than the 2% found in the study of travelers from the Netherlands conducted during 2006–2007 (8) and the 6% found in the study of Boston, Massachusetts, USA, area travelers conducted during 2009–2010 (15). However, seroprevalence in this study was lower than the 27% found in the study of blood donors from the Netherlands conducted during 2011 (16) and in the population of Amsterdam during 2004 (17). Although these differences should also be interpreted with caution, there are several possible explanations for the differences in prevalence between studies.

The major difference in sensitivity between different assays could be an explanation for the higher prevalence we found than the prevalence of 2% found in the previous prospective study among travelers from the Netherlands. The test we used in our study was the same test used in the study of blood donors from the Netherlands (16) and for the population of Amsterdam (17). However, because HEV immunity increases with age and depends on ethnicity, the difference in characteristics between the different study groups could explain why we found a prevalence of 15% rather than 27%. Our study population was composed of mostly young persons of western origin.

Independent risk factors for previous HEV infection were being born in a nonwestern country and previous travel to subtropical and tropical regions, which can be explained by higher endemicity in nonwestern countries. Also, older age was a major risk factor for previous HEV infection, as observed by Sadik et al. (17).

A total of 9 of the 19 persons who showed seroconversion reported nonspecific symptoms possibly related to HEV infection. Only 1 of 31 hospitalized travelers showed seroconversion for antibodies against HEV, but hospitalization was probably not related to HEV infection (self-reported diagnosis was dehydration caused by diarrhea). None of the persons who showed seroconversion were given a diagnosis of HEV infection during the study. Because many cases of

---

### Table 2. Attack rates and incidence of seroconversions in HEV antibody levels for 515 long-term travelers to subtropical and tropical countries, the Netherlands, December 2008–September 2011*

| Characteristic                  | Travelers at risk | HEV seroconversions | Attack rate, % (95% CI) | Person-weeks of travel | Incidence/1,000 person-weeks (95% CI) | Univariable analysis |
|--------------------------------|-------------------|---------------------|-------------------------|------------------------|---------------------------------------|----------------------|
| Total                          | 515               | 19                  | 3.7 (2.4–5.7)           | 10,715                  | 1.8 (1.1–2.8)                        |                      |
| Median age, y (IQR)            | 25 (23–29)        | 26 (22–31)          |                         |                        |                                       |                      |
| Sex                            |                   |                     |                         |                        |                                       |                      |
| F                              | 335 (65)          | 9                   | 2.7 (1.4–5.0)           | 6,795                   | 1.3 (0.7–2.5)                        | 1.0 (0.8–4.7)        |
| M                              | 180 (35)          | 10                  | 5.6 (3.0–9.9)           | 3,920                   | 2.6 (1.4–4.7)                        | 1.9 (0.8–4.7)        |
| Region of birth                |                   |                     |                         |                        |                                       |                      |
| Western                        | 506 (98.3)        | 19                  | 3.8 (2.4–5.8)           |                        |                                       |                      |
| Nonwestern                     | 9 (1.7)           | 0                   | NA                      |                        |                                       |                      |
| Purpose of travel              |                   |                     |                         |                        |                                       |                      |
| Holiday                        | 324 (62.9)        | 10                  | 3.1 (1.7–5.6)           | 6,556                   | 1.5 (0.8–2.8)                        | 1.0 (0.5–3.3)        |
| Work or study                  | 184 (35.7)        | 8                   | 4.3 (2.2–8.3)           | 3,970                   | 2.0 (1.0–4.0)                        | 1.3 (0.4–27.0)       |
| VFR                            | 7 (1.4)           | 1                   | 14.3 (2.6–51.3)         | 1,885                   | 5.3 (0.9–29.4)                       | 3.5 (0.4–27.0)       |
| Primary region of travel       |                   |                     |                         |                        |                                       |                      |
| Southeast Asia and Oceania     | 172 (33.4)        | 5                   | 2.9 (1.2–6.6)           | 3,543                   | 1.4 (0.6–3.3)                        | 1.0 (0.5–3.7)        |
| South America                  | 148 (28.7)        | 5                   | 3.4 (1.5–7.7)           | 3,211                   | 1.6 (0.7–3.6)                        | 1.1 (0.3–3.8)        |
| Sub-Saharan Africa             | 94 (18.3)         | 2                   | 2.1 (0.6–7.4)           | 1,972                   | 1.0 (0.3–3.7)                        | 0.7 (0.1–3.7)        |
| Southern Asia                  | 47 (9.1)          | 3                   | 6.4 (2.2–17.2)          | 898                     | 3.3 (1.1–9.8)                        | 2.4 (0.6–9.9)        |
| Central America and Caribbean  | 37 (7.2)          | 3                   | 8.1 (2.8–21.3)          | 754                     | 4.0 (1.4–11.6)                       | 2.8 (0.7–11.8)       |
| Asia, other                    | 17 (3.3)          | 1                   | 5.9 (1.0–27.0)          | 336                     | 3.0 (0.5–16.7)                       | 2.1 (0.2–18.1)       |
| Travel duration, wk            |                   |                     |                         |                        |                                       |                      |
| 12–16                          | 189 (36.7)        | 6                   | 3.2 (1.5–6.8)           | NA                     |                                       |                      |
| 17–24                          | 190 (36.9)        | 7                   | 3.7 (1.8–7.4)           | NA                     |                                       |                      |
| 25–52                          | 136 (26.4)        | 6                   | 4.4 (2.0–9.3)           | NA                     |                                       |                      |
| Hospital admission             |                   |                     |                         |                        |                                       |                      |
| No                             | 484 (94)          | 18                  | 3.7 (2.4–5.8)           | 10,032                  | 1.8 (1.1–2.8)                        | 0.8 (0.11–6.11)      |
| Yes                            | 31 (6)            | 1                   | 3.2 (0.6–16.2)          | 682.5                   | 1.5 (0.3–8.2)                        | 1.0 (0.8–4.7)        |

*Values are no. (%) except as indicated. HEV, hepatitis E virus; IQR, interquartile range; IRR, incidence rate ratio; NA, not applicable; VFR, visiting friends and relatives.
hepatitis E are subclinical in otherwise healthy persons and only immunocompetent travelers were included in our study, it is not surprising that so many persons who showed seroconversion did not report specific symptoms.

The strength of our study is that it is a prospective study in which blood samples before and after travel and diaries kept during travel were available for all 604 long-term travelers. However, our study also had limitations. Because this study was part of a larger study, the travel diary contained general clinical symptoms instead of hepatitis E–specific symptoms. Thus, we could have missed signs of a mild clinical HEV infection. Also, the median interval between obtaining a posttravel blood sample and return from travel was only 25 days. Because the incubation period for hepatitis E is 15–60 days, this period could have led to an underestimation of cases. However, because this study involved long-term travelers who traveled for 12–52 weeks, it is unlikely that many infections were contracted in the last weeks of travel. Therefore, we assume the short interval between return from travel and obtaining a blood sample had limited consequences for the final results. In addition, the median interval between obtaining the first blood sample and travel departure was 38 days. Therefore, persons who showed seroconversion might have contracted the virus before travel, which could have led to overestimation of travel-related attack rates and incidences, but we assume this had limited effect on the final results.

We assumed that persons with HEV IgG were protected against reinfection and did not include them in additional analyses. However, reinfection is possible, even in immunocompetent persons (1,4). We compared pretravel and posttravel sample titers and found only 1 person with a high posttravel titer and a much lower but still above the positive threshold pretravel titer. This result could have been a reinfection, but a low false-positive value for the pretravel sample is also possible. We considered this traveler immune in our additional analysis; this person also did not report any symptoms of HEV infection. A 4-fold increase in titer between pretravel and posttravel samples was not found for other persons.

Our study could have had a selection bias because all participants sought pretravel health advice in which advice on personal hygiene was stressed. Because genotypes 1 and 2 of HEV are contracted through the fecal–oral route, this finding could have led to an underestimation of HEV incidence. However, most (82%) travelers in our cohort experienced travelers’ diarrhea, which could also be contracted through the same route. Therefore, we believe that this selection bias had limited consequences on the outcome.

Finally, seroprevalence research most often lacks a diagnostic standard because it resembles a postinfection status in which confirmatory tests using PCR are not feasible. In previous studies, the HEV IgG ELISA appeared to be one of the most sensitive tests available (18–21). However, in the absence of World Health Organization HEV-negative reference material, studies investigating the specificity of the test are scarce. Although results from a study in France were promising (specificity 97.8%) (21), possible false-positive test results cannot be excluded.

Using the HEV IgG ELISA, we found an attack rate for HEV infection of 3.7% and an incidence of 1.8 cases/1,000 person-weeks, which are higher than values from previous prospective studies. This finding could be a reflection of an increasing risk for travelers, but it could also (partially) reflect improved sensitivity of the available test. Almost half of persons who showed seroconversion had mild, non-specific clinical symptoms possibly associated with HEV infection. Therefore, HEV infection does not seem to be a major problem in healthy immunocompetent travelers. However, rare fulminating liver failure in immunocompetent travelers has been reported (2), and in pregnant women and immunocompromised travelers, the risk for severe or fatal disease is much higher. Because travel has increased during the past few decades, at-risk groups also travel more (22). Good sanitation and clean drinking water should be discussed in all travel health advice. If an HEV vaccine were approved and found to be safe and effective for pregnant women and immunocompromised travelers, these vulnerable travelers could especially benefit from its protection.

Acknowledgments
This study was conducted within the Amsterdam Academic Collaborative Center on Public Health, which is a collaboration between the Public Health Service of Amsterdam and the Academic Medical Center of the University of Amsterdam, the Netherlands. We thank the physicians and nurses at the travel clinic of the Public Health Service Amsterdam for assistance in data collection, and Sanne Belderok, Joan Kint, and Claire Buswell for editorial review.

The Amsterdam Academic Collaborative Center on Public Health is supported by the Netherlands Organization for Health Research and Development (grant no. 7115 0001).

About the Author
Dr. Elfrink is a physician at the travel clinic of the Public Health Service, Amsterdam, the Netherlands, and the National Coordination Centre for Traveller’s Health Advice, Amsterdam. Her primary research interest is the epidemiology of travel-related infectious diseases.

References
1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379:2477–88.
   http://dx.doi.org/10.1016/S0140-6736(11)61849-7
2. Chris RB, Keystone JS. Fulminant hepatic failure from hepatitis E in a non-pregnant female traveller. J Travel Med. 2016; 23:taw021. http://dx.doi.org/10.1093/jtm/taw021
3. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27:116–38. http://dx.doi.org/10.1128/CMR.00057-13

4. World Health Organization. Hepatitis E vaccine: WHO position paper, May 2015. Wkly Epidemiol Rec. 2015;90:185–200.

5. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367:1237–44. http://dx.doi.org/10.1056/NEJMra1204512

6. Swaminathan A, Torresi J, Schlangenhaus P, Thursky K, Wilder-Smith A, Connor BA, et al.; GeoSentinel Network. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect. 2009;59:19–27. http://dx.doi.org/10.1016/j.ijinf.2009.05.008

7. Lachish T, Tandlich M, Schwartz E. Acute hepatitis in Israeli travellers. J Travel Med. 2013;20:232–6. http://dx.doi.org/10.1111/jtm.12039

8. Elfrink F, van Rijckevorsel GG, van Goor T, van den Hoek A, Sonder GJ. Low risk of hepatitis E among Dutch short-term travelers. J Travel Med. 2012;19:202–4. http://dx.doi.org/10.1111/j.1708-8305.2012.00597.x

9. Potasman I, Koren L, Peterman M, Srugo I. Lack of hepatitis E infection among backpackers to tropical countries. J Travel Med. 2000;7:208–10. http://dx.doi.org/10.2310/7060.2000.00062

10. Smalligan RD, Lange WR, Frame JD, Yarbough PO, Frankenfield DL, Hyams KC. The risk of viral hepatitis A, B, C, and E among North American missionaries. Am J Trop Med Hyg. 1995;53:233–6. http://dx.doi.org/10.4269/ajtmh.1995.53.233

11. Ooi WW, Gawoski JM, Yarbough PO, Pankey GA. Hepatitis E seroconversion in United States travelers abroad. Am J Trop Med Hyg. 1999;61:822–4. http://dx.doi.org/10.4269/ajtmh.1999.61.822

12. World Health Organization. International travel and health. Geneva: The Organization; 2008.

13. Gunaratnam P, Tobin S, Seale H, McAnulty JM. Infectious diseases in returned travellers, NSW, 2010–2011. N S W Public Health Bull. 2014;24:171–5.

14. Heywood AE, Zwar N, Forssman BL, Seale H, Stephens N, Musto J, et al. The contribution of travellers visiting friends and relatives to notified infectious diseases in Australia: state-based enhanced surveillance. Epidemiol Infect. 2016;Aug 30:1–10.

15. Barbé KA, Jentes ES, Drobeniuc J, Kamili S, Hamer DH, Barnett ED. Seroprevalence of hepatitis E among Boston area travelers, 2009–2010. Am J Trop Med Hyg. 2017;96:929–34.

16. Slot E, Hogema BM, Riezebos-Brilman A, Kok TM, Molier M, Zaaijer HL. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill. 2013;18:2050. http://dx.doi.org/10.2807/1560-7917.ES2013.18.31.20550

17. Sadik S, van Rijckevorsel GGC, van Rooijen MS, Sonder GJB, Bruisten SM. Seroprevalence of hepatitis E virus differs in Dutch and first generation migrant populations in Amsterdam, the Netherlands: a cross-sectional study. BMC Infect Dis. 2016;16:659. http://dx.doi.org/10.1186/s12879-016-2007-z

18. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82:799–805. http://dx.doi.org/10.1002/jmv.21656

19. Pas SD, Strevelker RH, Pronk M, de Man RA, Beersma MF, Osterhaus AD, et al. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol. 2013;58:629–34. http://dx.doi.org/10.1016/j.jcv.2013.10.010

20. Kmush BL, Labrique AB, Dalton HR, Ahmed ZB, Ticehurst JR, Heaney CD, et al. Two generations of “gold standards”: the impact of a decade in hepatitis E virus testing innovation on population seroprevalence. Am J Trop Med Hyg. 2015;93:714–7. http://dx.doi.org/10.4269/ajtmh.15-0159

21. Abravanel F, Chapuy-Regaud S, Lhomme S, Miedougé M, Peron JM, Alric L, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol. 2013;58:624–8. http://dx.doi.org/10.1016/j.jcv.2013.10.003

22. Elfrink F, van den Hoek A, Sonder GJ. Trends and characteristics among HIV-infected and diabetic travelers seeking pre-travel advice. Travel Med Infect Dis. 2014;12:79–83. http://dx.doi.org/10.1016/j.tmaid.2013.06.009

Address for correspondence: Floortje Elfrink, Department of Infectious Diseases, Public Health Service, Nieuwe Achtergracht 100, 1018 WT Amsterdam, the Netherlands; email: felfrink@ggd.amsterdam.nl